Retina Revolution: Maximizing Vision, Minimizing Burden in the Treatment of Neovascular Retinal Diseases
CLICK "CONTINUE" AT THE BOTTOM OF THE PAGE TO COMPLETE YOUR REGISTRATION TO JOIN US IN SAN ANTONIO.
Can't make it to San Antonio? Click “Continue” AT THE BOTTOM OF THE PAGE AND select the live streaming option to participate virtually.
Sunday, October 10, 2021
Buffet Dinner: 5:30 PM – 6:00 PM CT
Symposium: 6:00 PM – 7:30 PM CT
LIVE SYMPOSIUM
Co-Chairs
Jeffrey S. Heier, MD
Director, Retina Service
Director, Retina Research
Ophthalmic Consultants of Boston
Boston, MA
Arshad M. Khanani, MD, MA, FASRS
Managing Partner, Director of Clinical Research, Director of Fellowship
Sierra Eye Associates
Clinical Associate Professor
University of Nevada, Reno School of Medicine
Reno, NV
This program is not endorsed by the ASRS.
This activity is provided by Paradigm Medical Communications, LLC.
Disclosure of Financial Support
This activity is supported by an educational grant from Genentech, a member of the Roche Group.
Target Audience
This activity is designed to meet the educational needs of retina specialists. It may also benefit comprehensive ophthalmologists and other clinicians who are involved in the care of patients with neovascular retinal diseases.
Statement of Need
Treatment of neovascular retinal diseases with intravitreal anti-vascular endothelial growth factor (VEGF), the long-running standard of care, is limited by a need for frequent repeat injections to derive optimal visual outcomes. The high treatment burden is associated with undertreatment (and, consequently, suboptimal visual outcomes) in the real world versus clinical trials. Innovative agents and delivery devices in late-phase investigation have the potential to upend onerous treatment paradigms while maintaining (and possibly even enhancing) efficacy. This education will familiarize retina specialists with the science behind impending breakthroughs (both novel agents and delivery devices and techniques) that are poised to revolutionize the management of a variety of neovascular retinal diseases, so they are prepared to embrace the practice changes warranted.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Identify components of the Ang/Tie2 pathway that affect vascular stability, contributing to the pathophysiology of neovascular retinal diseases
- Evaluate clinical trial designs, safety, and efficacy for novel strategies under investigation for durable and sustained treatment of neovascular retinal diseases
- Describe appropriate surgical techniques for the implantation and/or refill of novel anti-VEGF delivery devices, as well as common pitfalls that should be avoided
Agenda
5:30 – 6:00 PM Registration and Complimentary Buffet Dinner
6:00 – 6:05 PM Treatment of Neovascular Retinal Diseases: The need for Change
6:05 – 6:40 PM New Paths to Enhanced Vascular Stability
6:40 – 7:15 PM Emerging Options for Sustained Delivery
7:15 – 7:30 PM Q&A
Physician Accreditation Statement
Paradigm Medical Communications, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physician Credit Designation Statement
Paradigm Medical Communications, LLC designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
PA Continuing Education
PAs may claim a maximum of 1.5 Category 1 credits for completing this activity. NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society.
Nurse Practitioner Continuing Education
The American Academy of Nurse Practitioners Certification Program (AANPCP) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. Individuals are responsible for checking with the AANPCP for further guidelines.
Disclosure of Conflicts of Interest
In accordance with ACCME requirements on disclosure information about relationships with ineligible companies (if any) for anyone contributing to content development will be included in materials distributed at the time of the activity.
CME Inquires: For questions regarding CME credit, contact the Paradigm CME Department at (845) 398-5949 or cme@paradigmmc.com.
Fee Information
There is no fee required for participation in this activity.
© 2021 Paradigm Medical Communications, LLC except where noted. Content may not be reproduced in whole or part without the express written permission of Paradigm Medical Communications, LLC.
Click "Continue" to complete your registration.